key: cord-0760197-vyaijm05
authors: Lobaloba Ingoba, Line; Djontu, Jean Claude; Mfoutou Mapanguy, Claujens Chastel; Mouzinga, Freisnel; Diafouka Kietela, Steve; Vouvoungui, Christevy; Kuisma, Eeva; Nguimbi, Etienne; Ntoumi, Francine
title: Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo
date: 2022-01-15
journal: IJID Regions
DOI: 10.1016/j.ijregi.2022.01.002
sha: 9f3e7e4cb649aeaac6fdeb6edb254d4806b8fcf0
doc_id: 760197
cord_uid: vyaijm05

Objectives : As limited data are available from Central Africa, the aim of the present study was to evaluate the anti-SARS-CoV-2 Ab prevalence in indigenous residents, in Bomassa, a village located in the Sangha Region in the Republic of Congo. Methods : Plasma and oropharyngeal swabs samples were collected from 304 healthy adult individuals, randomly recruited in May 2021 before vaccine introduction in the area. In addition, 82 plasma samples from the same area in 2019 were included as controls for cross-reaction investigation against other Coronaviruses. The SARS-CoV-2 virus was detected by qRT-PCR and sequenced using Next-Generation Sequencing. ELISA method was used for detecting IgG, IgM and neutralizing Ab against SARS-CoV-2 antigens. Results : About 4.9% (15/304) of the participants were SARS-CoV-2 positive and B.1.631 was the only variant identified. Of 109 individuals harboring anti-SARS-CoV-2 IgG and/or IgM Ab, 45.9 % (50/109) had anti-SARS-CoV-2 neutralizing Ab. A proportion of 3.7% (3/82) of control samples collected before the pandemic were positive to IgG, but negative for neutralizing Ab. Conclusions : While seroprevalence against SARS-CoV-2 represented 25% in indigenous population, almost 50% of seropositive participants had neutralizing antibodies. This finding highlights that the spread of the SARS-COV2 infection is under-estimate in the country.

The Coronavirus Disease 2019 Diagnosis of SARS-COV-2 infection is based on reliable testing, and to determine the spread of the disease is highly dependent of the capacity of testing (Kobia and Gitaka 2020) , which can be a challenge especially in rural areas of sub-Saharan Africa (United.Nations 2020).

Seroepidemiological studies have reported the presence of specific IgM and IgG Ab against SARS-CoV-2 virus (Graham 2020; Zhu et al. 2020) , which seem to persist from some days (IgM) to many months (IgG) (WHO 2020). Thus, several antibody-based serologic rapid diagnostic tests (Graham 2020; Zhu et al. 2020) , and ELISA tests (CDC 2020), have been developed, for the detection of the current or past SARS-CoV-2 infection.

The seroprevalence of anti-SARS-CoV-2 IgG was 42.3% among truck drivers and assistants in Kenya (Uyoga et al. 2021) , 42% amongst blood donors in Nigeria,45% in Frontline Health Workers with no COVID-19 symptoms from Ibadan, Nigeria (Olayanju et al. 2021 ), 40% in public sector patients in Cape Town, South Africa (Hsiao. et al. 2020) , and samples from sub-Saharan Africa had higher cross-reactivity against SARS-CoV-2 than those from the America and Europe (Nkuba Ndaye et al. 2021) .

A recent cohort study from United Kingdom reported the association of a past history of SARS-CoV-2 infection with an 84% low risk of re-infection, with a median protective effect observed 7 months following primary infection (Hall et al. 2021) , showing that previous infections provide strong immunity to future infections. This evidence has been confirmed by another report showing the persistence SARS-CoV-2 specific IgG secreting memory B cells and durable CD8 and CD4 T cells recognizing distinct viral epitope regions in many individuals for over 200 days of post infection (Cohen et al. 2021) . These findings suggest that reduced doses of vaccine as compared to current recommended doses, might be sufficient for Ab response boosting in individuals having acquired naturally anti-SARS-CoV-2 Ab. Thus, data on natural anti-SARSCoV-2 Ab response might help for the improvement of the vaccination strategies in non-vaccinated population.

The Republic of Congo reported its first SARS-CoV-2 infection case in March 14 th 2020 and a total of 13,493 cases has been identified and 179 deaths deplored within the17 first months of the pandemic in the country (SITREP-171 2021). To date, only seroprevalence data from Brazzaville, the capital have been reported as it concentrates more than 60% of the cases. Limited RT-PCR testing capacities have an impact on the real evaluation of the pandemic in the country particularly in remote regions like the Sangha region (North of the Republic of Congo) where since the beginning of the pandemic a total of 154 cases were reported so far with 130 cases in August 2020 and 15 cases in April 2021 (SITREP-141 and SITREP-146, 2021) . Therefore, the anti-SARS-CoV-2 seroprevalence was investigated in the Bomassa village, situated in the rainforest in the Sangha Region. The collected data will contribute to improve the implementation of preventive measures including vaccination strategies in the community.

The study protocol was reviewed and approved by the Institutional Ethics Committee of the Congolese Foundation for Medical research (Ethical Clearance nº030/CIE/FCRM/2020). Participation in the study was voluntary with written inform consent from each individual. The reverse transcription PCR (qRT-PCR) for SARS-CoV-2 diagnosis was performed for each participant at the time of enrollment, and the positive results were reported to the physician for better care according to national policy.

This descriptive cross-sectional study was conducted in Bomassa village. Bomassa (2°12'N, 16°11'E) is a locality in northern Republic of Congo, lying on the Sangha River and the border with Central African Republic (Fig 1) . It is situated at 800 m far from the Nouabale-Ndoki national park, and is known for its local rainforests, home to wide variety of large mammals. The inhabitants of the village are mostly indigenous (Pygmies and Bantous), illiterate at the majority (61%), with hunting, fishing, and fruit picking as their main activities. .

The study was carried out in May 20 th and June 2 nd 2021. A total of 304 Congolese aged from 18 to 60 years old with no related known COVID-19 symptoms were randomly recruited across all the Bomassa village. In addition, 82 plasma samples collected from the individuals living in the same area between June and July 2019 (before COVID-19 pandemic) were included in the analysis as controls for the investigation of cross reaction between SARS-CoV-2 antigens and Ab induced by others corona viruses antigens.

Information on the participant's health, age, address and sex was collected using a standard questionnaire. Oropharyngeal swabs collected in viral transport media were transported at -80° C to the laboratory for the diagnosis of SARS-CoV-2 infection by qRT-PCR and the sequencing of the virus. Peripheral blood samples collected in EDTA tubes from each participant, were centrifuged and the obtained plasma stored at -80° C for antibody assay.

SARS-CoV-2 was detected using multiplex qRT-PCR kit according to the manufacturer's protocol. Briefly, total nucleic acid extraction was performed using QIAamp RNA mini kit (Qiagen GmbH, Hilden, Germany). One hundred forty (140) µL of the supernatant was used to yield a nucleic acid elution volume of 50 µL. The detection of SARS-CoV-2 was performed by qRT-PCR using a Light-Cycler 480 Instrument II (Roche Diagnostics, Mannheim, Germany) and RealStar SARS-CoV-2 RT-PCR kit 1(altona diagnostic, Germany), according to the manufacturer's protocol. This kit utilizes three probes: the first targets E gene specific for B-βCOV, the second probe targets S gene specific for SARS-COV-2, and the last targets the internal control (IC). All specimens with S gene probe cycle threshold (Ct) less than or equal to 30 were considered positive.

For all SARS-CoV-2 positive samples, a cDNA synthesis was performed with NEB LunaScript RT SuperMix Kit (E3010) using 8 µl of extracted viral RNA and 2 µl of LunaScript RT SuperMix (5x) according to manufacturer's instructions. Direct amplification of the viral genome cDNA was performed. After synthesis, cDNA was amplified using 29 couples of multiplex primers subdivided in 2 pools (15 and 14 couples of primers in pool1 and pool 2 respectively). Each couple of primers amplified a length DNA fragment of 1200 bp. PCR amplification was carried out using Q5 Hot Start DNA Taq Polymerase with 2.5 µl of cDNA in a 22.5 µl reaction volume of the Mix. The PCR program used in this experiment was the following: an initial step of 98 °C for 30 s, then 35 cycles of 98 °C for 15 s followed by five minutes at 65 °C. After PCR, amplicons from both pools were mixed and validated using agarose gel electrophoresis.

A volume of 45 µl of PCR amplicoms was purified by AMPure XP Beads. Briefly, for each sample, 25 µl of beads were added, following by washing steps and elution with 20 µl of 10 mM Tris, HCl, 50 mM NaCl, PH 7.5-8. Three µl of the purified DNA were used to quantify nucleic acid, in order to normalize the concentration to 100 ng in a volume of 7.5 µl for each sample. Then, 2.5 µl of corresponding barcode was added to each sample and the incubation performed at 30°C for 1 minute and then at 80°C for 1 minute. Samples with barcode were pooled in the single tube and the purification as well as elution of 10 µl of DNA performed. Adapter ligation and cleanup was performed using the Oxford Nanopore kit according to manufacturer specifications. Libraries were sequenced on the Nanopore MinION device using FLO-MIN106D flow cells. Read quality filtering, sequence reads were aligned to a SARS-CoV-2 reference genome sequence and consensus sequence generation was performed using ARTIC Network software. Isolate lineages were determined with PANGOLIN, and consensus genome sequences deposited in the GISAID database.

The IgG and IgM Ab against SARS-CoV-2 antigens were measured using Virotech SARS-CoV-2 IgG, IgM ELISA kit (Virotech Diagnostics GmbH, Germany) according to the manufacturer's protocol. The Virotech Unit (VU) or the cut-off value for seropositivity of 

The presence of anti-SARS-CoV-2 Ab in the study participants plasma was 

Graph Pad Prism 6.0.1was used for the statistical analyses. Continuous variables were reported as medians with interquartile range (IQR), while categorical variables were reported as percentages and were compared using Fisher's exact test or Khi square test. P values <0.05 were considered statistically significant.

The characteristics of individuals enrolled in this study are summarized on the Table   1 

Of 15 positive samples detected in the present study, those with low Ct were subjected to sequencing. All sequences corresponded to B.1.631 lineage belonging to clade G. It was found that all sequences carried the E484K mutation and many additional mutations of interest like Spike P681H, Spike A243del, Spike D614G, Spike H69del, Spike H245Y, Spike L242del, Spike L244del, and Spike P26S.

During an investigation conducted in June and July 2019, healthy adults residing in Bomassa were enrolled and venous blood sample collected for planned immunological investigations. A total of 82 plasma samples from residents who provided consent for future use of their biological materials, were tested in 2021 for the presence of total IgG against SARS-CoV2. Among the 82 plasmas, 3 were positive to anti-SARS-CoV-2 IgG Ab, providing a prevalence of 3.7% (Figure 2 ). These three (3) anti-SARS-CoV-2 IgG positive plasmas were tested negative using the neutralizing assay.

Overall, the seroprevalence of anti-SARS-CoV-2 Ab were 28.6% (87/304) for IgG and 12.5% (38/304) for IgM in enrolled individuals, respectively ( Figure 2, Table 3 ).

However, the seroprevalence of IgG Ab was significantly higher in SARS-CoV-2 qRT-PCR + individuals (53.3%, 8/15) compared to SARS-CoV-2 qRT-PCRindividuals (27.3%, 79/289) (p = 0.04), while the seroprevalence of IgM Ab did not differ between SARS-CoV-2 qRT-PCR + individuals (13.3%, 2/15) and SARS-CoV-2 qRT-PCRindividuals (12.3%, 36/289) (p = 0.99).

The anti-SARS-CoV-2 IgG and IgM Ab prevalence did not differ significantly according to age groups (Table 3 ). In addition, the seroprevalence the IgG and IgM Ab was not significantly different between males (28.8% and 12.9% respectively), and females (28.2% and 11.8% respectively).

The seroprevalence of anti-SARS-CoV-2 neutralizing Ab represented 45.9% (50/125) in IgG and /or IgM positive individuals (Fig.3) . Individuals harboring only IgG Ab were more frequently positive to neutralizing Ab (56.9%, 37/65) compared to individuals harboring IgM Ab exclusively (18.2%, 4/22), and those harboring both IgM and IgG Ab (14.4%, 2/14) (data not shown). The seroprevalence of the neutralizing Ab was not significantly higher in SARS-CoV-2 qRT-PCRindividuals (46.5 %,) compared to SARS-CoV-2 qRT-PCR + individuals (37.5%,) (p= 0.72) ( Table 3 ). Sex and age had no impact on the seroprevalence of neutralizing Ab (Fig 4A and B ).

The present study aimed at evaluating the anti-SARS-CoV-2 Ab prevalence in Congolese individuals with no known related COVID-19 symptoms, living in Bomassa village. The results indicated that 29%, and 12.5% of individuals harbored anti-SARS-CoV-2 IgG and IgM, respectively. Therefore, it could be stated that more than 25% of indigenous population living in Bomassa village, might have been in contact with SARS-CoV-2 to which they have produced specific IgG and/or IgM antibodies, with about 12.5% of recent exposure.

The prevalence of anti-SARS-CoV-2 Ab found in the present study is either higher or lower compared to the estimates found in the majority of previous studies carried out across the African continent. In fact, the surveys carried out in Nigeria showed the anti-SARS-CoV-2 seroprevalence ranged from 25 to 45% depending on the population sampled (Olayanju et al. 2021; Nna et al. 2021; Majiya et al. 2021) . Similarly, The seroprevalence of Ab against the virus was 40% in public sector patients in Cape Town, South Africa (Hsiao. et al. 2020 ), 12% (8.2 -16.5) among asymptomatic healthcare workers in Blantyre, Malawi (Chibwana et al. 2020) , and 25 % among gold mine workers in Côte d'Ivoire (Milleliri et al. 2021) . In Addis Ababa, Ethiopia, the Ab seroprevalence among those reporting no close contact with SARS-CoV-2 infected individuals was 9% in April 2020 (Alemu et al. 2020 ). This seroprevalence of Ab against SARS-CoV-2 virus was lower at 4.3% (2.9 -5.8) in blood donors in Kenya in June (Uyoga et al. 2021 ), increasing to 9% (7.6 -10.8) by September 2020 (Adetifa et al. 2021) .

The higher or lower anti-SARS-CoV-2 Ab prevalence observed in this study compared to previous reports may be due to the differences in SARS-CoV-2 epidemiology in different locations, time periods, or sub-populations as well as difficulties access to vaccination. In fact, the present study was carried out from May to June 2021 in rural area, conversely to the majority of previous reports which were carried out during the 5 first months of the pandemic in 2020, and mostly in cities which are densely populated. In addition, the used of non-international standardized serological tests may themselves contribute to the differences; a study in Kinshasa, Democratic Republic of the Congo showed that seropositivity in health facility staff ranged from 8% to 36% depending on the serological test used (Iyer et al. 2020) . These studies ttogether indicate that SARS-CoV-2 has spread widely in sub-Saharan Africa including in rural areas. Antibody titers have been shown to be important for the evaluation of protective anti-SARS-CoV-2 Ab response. The lack of anti-SARS-CoV-2 standard IgG and IgM Ab did not allow to determine these parameters in the present study. Nevertheless, the ELISA test used in this study is more sensitive compared to antibody-based serologic immunochromatographic tests which were used in over 50% of previous seroepidemiological studies carried out in Africa (Olayanju et al. 2021; Majiya et al. 2021; Nna et al. 2021) The estimate level of SARS-CoV-2 spread reported by this study in Bomassa village represents the alarm raised to the health authorities who should reinforce the COVID-19 preventive measures in this vulnerable population. The COVID-19 represents a grave heath threat to this indigenous community which already experience poor access to healthcare, significantly higher rates of communicable diseases, lack of access to essential services, sanitation, and other key preventive measures, such as clean water, soap, and disinfectant (United.Nations 2020) In the present study, 45.8% (50/109) of individuals harboring IgG and/or IgM Ab had anti-SARS-CoV-2 neutralizing Ab. This is consistent with a cohort study having reported the association of a previous history of SARS-CoV-2 infection with the persistence of SARS-CoV-2 specific IgG secreting memory B cells and durable specific CD8 and CD4 T cells in many individuals for over 200 days of post infection (Cohen et al. 2021) , and suggest a potential contribution of natural SARS-CoV-2 infection to acquired Ab mediated immunity against COVID-19. In other hand, the detection of anti-SARS-CoV-2 IgG Ab in 3.7% of plasma sample collected in Bomassa village before COVID-19 pandemic is in agreement with previous studies showing the existence of the cross-reaction of the tests with other circulating coronavirus in African countries that could lower their specificity. In fact, the presence of pre-existing antibodies recognizing SARS-CoV-2 in uninfected individuals due to seasonal coronaviruses was also identified by Ng et al. (Ng et al. 2020) whereas Tso and colleagues (Tso et al. 2021) showed that pre-pandemic samples from sub-Saharan Africa had higher cross-reactivity against SARS-CoV-2 than those from the USA. Among the 3 prepandemic plasma tested positive to anti-SARS-CoV-2 IgG in the present study, none of the samples was positive to anti-SARS-CoV-2 neutralizing Ab, suggesting the high specificity of the Ab neutralization test used in the study.

Although males and females are known to differ in their immunological responses to foreign pathogens, conflicting data have been reported concerning the sex and anti-SARS-CoV-2 Ab response with some reports showing higher prevalence IgM Ab in females than in males (Borges et al. 2020) , others showing no association between these Ab and sex (Uyoga et al. 2021; Adetifa et al. 2021 ). In the present study, no significant impact of sex or age was found on the assayed anti-SARS-CoV-2 Ab prevalence, suggesting that Ab response against SARS-CoV-2 in Bomassa village as well as the viral spread would be similar in males and females individuals.

Among the 15 SARS-CoV-2 qRT-PCR + individuals found in this study, 7 (46.6%) individuals were negative to anti-SARS-CoV-2 Ab. Since these individuals had active SARS-CoV-2 infection, the question becomes, why didn't they produce detectable Ab against the virus? Several explanations seem feasible. First, some of the individuals may have become infected too close to the date of sample collection to have produced Ab.

Second, the SARS-CoV-2 viral load would have been below the levels required to induce an immune response. Finally, all allelic forms of SARS-CoV-2 antigens were not used in this study, since some of these antigens have been shown to be very polymporphic (Ntoumi et al. 2021; Hou et al. 2020) , it possible that some individuals have Ab against SARS-CoV-2 antigens that were not detected. In support of this possibility are data from the study and others previous studies conducted in Africa. In fact, although B.1.631 was the only SARS-CoV-2 variant identified, all the sequences found in the present study carried the E484K mutation known with evidence of decreasing therapeutic/vaccine efficacy. Many others mutations of interest including P681H, Spike A243del, Spike D614G, Spike H69del, Spike H245Y, Spike L242del, Spike L244del, and Spike P26S were also identified in these sequences. These data are in line with the finding of previous report of Ntoumi et al carried out in Brazzaville where all SARS-CoV-2 genomes carried the spike mutation D614G (Ntoumi et al. 2021) , which has been associated with efficient replication ex vivo and transmission in vivo (Ntoumi et al. 2021) .

The results from the present study suggest that by the March 2021, about 25% of indigenous population living in Bomassa village, with no related known COVID-19 symptoms might have been in contact with SARS-CoV-2 and 4% presented asymptomatic infection. The detection of neutralizing Ab in almost 50% of IgG and /or IgM positive individuals of this study population suggest that these individuals are developing active protection against SARS-COV2 infection. In case of vaccination, these individuals would be eligible for one dose.

We are grateful to all participants to this study. We thank the participants of the study and Wildlife Conservation Society (WCS). FN is member of the Central Africa Clinical Network (CANTAM ) and PANDORA-ID-Net. JCD is supported by the Fondation MERIEUX.

This work was funded by PANDORA-ID-Net (EDCTP Grant Agreement RIA2016E-1609 and ITAIL project (EDCTP Grant agreement RIA2020EF-2947). Ab: Antibody. The seroprevalence of anti-SARS-CoV-2 Ab was compared between qRT-PCR + and qRT-PCRindividual groups using Fisher exact test. 

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

Sero-prevalence of anti-SARS-CoV-2 antibodies in Addis Ababa, Ethiopia

Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil

Centers for Disease control and prevention Vaccines COVID-19 phase 3

High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Rapid COVID-19 vaccine development

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

SARS-COV-2 seroprevalence in the Cape Town metropolitan sub-districts after the peak of infections

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

COVID-19: Are Africa's diagnostic challenges blunting response effectiveness?

Seroprevalence of COVID-19 in Niger State

SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Survey among Gold Mine Workers

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Challenges in interpreting SARS-CoV-2 serological results in African countries

Sero-prevalence of SARS-CoV-2 IgM and IgG antibodies amongst blood donors in Nigeria

Genomic surveillance of SARS-CoV-2 in the Republic of Congo

Asymptomatic Frontline Health Workers in Ibadan, Nigeria

Rapport de situation de la maladie à Corona virus, République du Congo

Rapport de situation de la maladie à Corona virus

High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

COVID-19 and Indigenous peoples

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

World Health Organization.The latest on the COVID-19 immunity and the current global situation

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind

FN, EK were involved in the study design. LLI, JCD, FM, SDK, CCMM collected and performed the samples: JCD, CV, LLI were involved in data analysis: All the authors contributed in writing the manuscript.

The authors declare no competing interests.